KR100743499B1 - 항염증용 조성물 - Google Patents
항염증용 조성물 Download PDFInfo
- Publication number
- KR100743499B1 KR100743499B1 KR1020050113102A KR20050113102A KR100743499B1 KR 100743499 B1 KR100743499 B1 KR 100743499B1 KR 1020050113102 A KR1020050113102 A KR 1020050113102A KR 20050113102 A KR20050113102 A KR 20050113102A KR 100743499 B1 KR100743499 B1 KR 100743499B1
- Authority
- KR
- South Korea
- Prior art keywords
- oh8dg
- oxo
- oh8g
- inhibits
- present
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (6)
- 8-옥소-구아노신, 8-옥소-데옥시구아노신 중 하나 이상의 성분을 유효성분으로 함유하는 항염증용 약학 조성물.
- 제 1항에 있어서, 8-옥소-데옥시구아노신을 유효성분으로 함유하는 항염증용 약학 조성물.
- 제 2항에 있어서, 상기 염증은 류마티스 관절염인 항염증용 약학 조성물.
- 제 2항에 있어서, 상기 염증은 홍반성 루푸스인 항염증용 약학 조성물.
- 제 2항에 있어서, 상기 염증은 다발성 경피증인 항염증용 약학 조성물.
- 제 2항에 있어서, 상기 염증은 성인 호흡곤란 증후군인 항염증용 약학 조성물.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020050113102A KR100743499B1 (ko) | 2005-11-24 | 2005-11-24 | 항염증용 조성물 |
PCT/KR2006/004951 WO2007061237A1 (en) | 2005-11-24 | 2006-11-23 | Composition for anti-inflammation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020050113102A KR100743499B1 (ko) | 2005-11-24 | 2005-11-24 | 항염증용 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20070054953A KR20070054953A (ko) | 2007-05-30 |
KR100743499B1 true KR100743499B1 (ko) | 2007-07-30 |
Family
ID=38067414
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020050113102A KR100743499B1 (ko) | 2005-11-24 | 2005-11-24 | 항염증용 조성물 |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR100743499B1 (ko) |
WO (1) | WO2007061237A1 (ko) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102200030B1 (ko) * | 2019-05-29 | 2021-01-08 | 가천대학교 산학협력단 | 8-옥소-2'-디옥시구아노신을 유효성분으로 포함하는 심정지 시 심장손상 방지용 조성물 |
KR102344674B1 (ko) * | 2019-06-19 | 2021-12-29 | 가천대학교 산학협력단 | 8-옥소-2'-디옥시구아노신을 유효성분으로 포함하는 이식용 장기의 보존 시 장기손상 방지용 조성물 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6403565B1 (en) | 1997-11-04 | 2002-06-11 | Pro-Neuron, Inc. | Antimutagenic compositions for treatment and prevention of photodamage to skin |
US20050026862A1 (en) | 2002-01-21 | 2005-02-03 | Beiersdorf Ag | Cosmetic or dermatological preparation |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004203784A (ja) * | 2002-12-25 | 2004-07-22 | Hayashibara Takeshi | 8−ハイドロキシ−2′−デオキシグアノシン生成抑制剤とその用途 |
-
2005
- 2005-11-24 KR KR1020050113102A patent/KR100743499B1/ko active IP Right Grant
-
2006
- 2006-11-23 WO PCT/KR2006/004951 patent/WO2007061237A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6403565B1 (en) | 1997-11-04 | 2002-06-11 | Pro-Neuron, Inc. | Antimutagenic compositions for treatment and prevention of photodamage to skin |
US20050026862A1 (en) | 2002-01-21 | 2005-02-03 | Beiersdorf Ag | Cosmetic or dermatological preparation |
Also Published As
Publication number | Publication date |
---|---|
WO2007061237A1 (en) | 2007-05-31 |
KR20070054953A (ko) | 2007-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Borea et al. | Pharmacology of adenosine receptors: the state of the art | |
Conti et al. | Coronavirus-19 (SARS-CoV-2) induces acute severe lung inflammation via IL-1 causing cytokine storm in COVID-19: a promising inhibitory strategy | |
Wang et al. | Taxifolin ameliorates cerebral ischemia-reperfusion injury in rats through its anti-oxidative effect and modulation of NF-kappa B activation | |
US20160122758A1 (en) | Agents for downregulation of the activity and/or amount of bcl-xl and/or bcl-w | |
Beshay et al. | The phosphodiesterase inhibitors pentoxifylline and rolipram suppress macrophage activation and nitric oxide production in vitro and in vivo | |
Yasui et al. | Theophylline accelerates human granulocyte apoptosis not via phosphodiesterase inhibition. | |
Haddad et al. | Immunopharmacological potential of selective phosphodiesterase inhibition. I. Differential regulation of lipopolysaccharide-mediated proinflammatory cytokine (interleukin-6 and tumor necrosis factor-α) biosynthesis in alveolar epithelial cells | |
Yu et al. | Paeoniflorin protects human EA. hy926 endothelial cells against gamma-radiation induced oxidative injury by activating the NF-E2-related factor 2/heme oxygenase-1 pathway | |
Yu et al. | The kinase inhibitor BX795 suppresses the inflammatory response via multiple kinases | |
JP2012526850A (ja) | サイクリン依存性キナーゼ阻害剤及びその用法 | |
Schumacher Jr | Febuxostat: a non-purine, selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with gout | |
Contreras et al. | Selective inhibition of phosphodiesterases 4A, B, C and D isoforms in chronic respiratory diseases: current and future evidences | |
Jonsson et al. | Mycophenolic acid inhibits inosine 5′-monophosphate dehydrogenase and suppresses production of pro-inflammatory cytokines, nitric oxide, and LDH in macrophages | |
Chen et al. | Potential targets for intervention against doxorubicin-induced cardiotoxicity based on genetic studies: a systematic review of the literature | |
KR100743499B1 (ko) | 항염증용 조성물 | |
EP1891961A1 (en) | Use of 5'-methylthioadenosine (mta) in the prevention and/or treatment of autoimmune diseases and/or transplant rejection | |
EP4218768A1 (en) | Combinations of imetelstat and venetoclax for use in the treatment of haematological cancer | |
EP3730144A1 (en) | Agent for treatment of nervous system disease | |
WO2003101276A2 (en) | Protective effects of pde-5 inhibitors | |
KR20070006943A (ko) | 핵전사인자 NF-κB의 활성화의 억제제로서의2-히드록시-4-트리플루오로메틸벤조산 유도체의 용도 | |
KR20210148866A (ko) | S-하이드록시클로로퀸을 사용한 홍반성 루푸스의 치료 | |
JP2011037722A (ja) | 小胞体ストレスによる神経細胞死の予防又は抑制剤 | |
Morsi et al. | Immunomodulatory, apoptotic and anti-proliferative potentials of sildenafil in Ehrlich ascites carcinoma murine model: In vivo and in silico insights | |
KR101270123B1 (ko) | 항산화용 조성물 | |
Bai et al. | Centipedegrass extracts regulate LPS-mediated aberrant immune responses by inhibiting Janus kinase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
N231 | Notification of change of applicant | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130704 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20140709 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20150723 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20160712 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20180123 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20190508 Year of fee payment: 13 |